Scancell Holdings (FRA:SCP) Institutional Ownership : 0.32% (As of May. 17, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Scancell Holdings Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Scancell Holdings's institutional ownership is 0.32%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Scancell Holdings's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Scancell Holdings's Float Percentage Of Total Shares Outstanding is 0.00%.

Scancell Holdings Institutional Ownership Historical Data

The historical data trend for Scancell Holdings's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings Institutional Ownership Chart

Scancell Holdings Historical Data

The historical data trend for Scancell Holdings can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	0.35	0.35	0.36	0.36	0.36	0.36	0.32	0.32	0.32	0.32

Scancell Holdings Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Scancell Holdings (FRA:SCP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (FRA:SCP) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

SCLP.GB:UK SCLP:UK

Address

Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD

Website

https://www.scancell.co.uk

Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (FRA:SCP) Headlines

No Headlines